BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Inclusion Criteria:

* 1\. Sign the written informed consent voluntarily;
* 2\. Age ≥ 18, ≤ 75, male or female;
* 3.Expected life ≥ 3 months
* 4\. The physical condition score of the Eastern Tumor Cooperative Organization (ECOG) is 0-2;
* 5.Biopsy sample or pathological wax slice test (within 1 year before signing the informed consent): target test positive
* 6\. According to RECIST v1.1 solid tumor evaluation criteria, there is at least one measurable lesion;
* 7\. Patients with recurrent/metastatic nasopharyngeal carcinoma who have received second-line or above system treatment failure in the past (Recurrence of nasopharyngeal carcinoma: nasopharyngeal carcinoma confirmed by pathology, after radical radiotherapy, the clinical tumor disappears completely, and after 6 months of treatment, local tumors with the same pathological type as the original tumor reappear; metastasis of nasopharyngeal carcinoma: tumor cells transfer from the primary site to distant organs through various ways, such as blood and lymph, and form tumor metastasis focus);
* 8\. It is possible to establish a single blood collection or venous blood collection channel, and there is no other blood cell separation contraindication;
* 9\. It has sufficient organ and bone marrow functions, as defined below

routine blood test

Neutrophil count (NEUT #) ≥ 1.0 × 10\^9/L

Platelet count (PLT) ≥ 80 × 10\^9/L

Hemoglobin concentration ≥ 90g/L

Liver function: subjects without liver metastasis

Aspartate aminotransferase (AST) ≤ 2.5 × Upper limit of normal value (ULN)

Alanine aminotransferase (ALT) ≤ 2.5 × Upper limit of normal value (ULN)

Total bilirubin (TBIL) ≤ 1.5 × ULN

Liver function: subjects with liver metastasis

Aspartate aminotransferase (AST) ≤ 5 × Upper limit of normal value (ULN)

Alanine aminotransferase (ALT) ≤ 5 × Upper limit of normal value (ULN)

Liver function: subjects with liver metastasis or Gilbert syndrome

Total bilirubin (TBIL) ≤ 2 × ULN

renal function

Creatinine clearance rate (CCR) ≥ 50mL/min

Coagulation function

International normalized ratio (INR) ≤ 1.5 × ULN

Activated partial thromboplastin event (APTT) ≤ 1.5 × ULN

* 10\. Toxic side effects left by early anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.) ≤ Level 1 (CTCAE5.0);
* 11\. During the study period and within 6 months after the last administration, subjects with fertility (male or female) must take effective medical contraceptive measures. Female subjects of childbearing age must have a pregnancy test within 72 hours before the first administration, and the result is negative.

Exclusion Criteria:

* 1\. Active central nervous system metastasis (except those that are stable after treatment);
* 2\. HIV positive or HBsAg positive, HBV DNA copy number is positive (quantitative test ≥ 1000 cps/ml) or HCV antibody is positive and HCV RNA is positive;
* 3\. Those who have mental or psychological diseases and cannot cooperate with the treatment and efficacy evaluation;
* 4\. Subjects with severe autoimmune diseases and long-term application of immunosuppressants;
* 5\. There is active infection or uncontrollable infection requiring systemic treatment within 14 days before signing the informed consent form;
* 6\. Any unstable systemic disease (including but not limited to): Active infection (except local infection);

Unstable angina pectoris;

Cerebrovascular ischemia or cerebrovascular accident (within 6 months before screening);

Myocardial infarction (within 6 months before screening);

Congestive heart failure (New York Heart Association \[HYHA\] classification ≥ Ⅲ);

Serious arrhythmia requiring drug treatment;

Heart disease needs treatment or hypertension is out of control after treatment (blood pressure\>160mmHg/100mmHg);

* 7\. Complicated with dysfunction of lung, brain, kidney and other important organs;
* 8\. Subjects had undergone major surgery or severe trauma within 4 weeks before signing the informed consent form, or were expected to undergo major surgery during the study period.
* 9\. Subjects received the last radiotherapy or anti-tumor treatment (chemotherapy, targeted therapy or immunotherapy) within 4 weeks before signing the informed consent form;
* 10\. The subject currently suffers from or has suffered from other malignant tumors that cannot be cured within 3 years, except for cervical cancer or skin basal cell cancer, and other malignant tumors with a disease-free survival period of more than 5 years;
* 11\. Have received T cells (including CAR-T and TCR-T) modified by chimeric antigen receptor within half a year before signing the informed consent form;
* 12\. Graft versus host disease (GVHD)
* 13\. Subjects who were receiving systemic steroid treatment before signing the informed consent form and who were judged by the investigator to need long-term use of systemic steroid treatment during the treatment period (except for inhalation or local use); And subjects treated with systemic steroids within 72 hours before cell reinfusion (except for inhalation or local use);
* 14\. Serious allergy or allergy history
* 15\. Subjects requiring anticoagulation treatment
* 16\. Pregnant or lactating women, or have a pregnancy plan within six months (for both men and women);
* 17\. The investigator believes that there are other reasons that cannot be included in the treatment